Xortx therapeutics receives final approval to list on the tsx venture exchange

Calgary, alberta, nov. 02, 2021 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (cse: xrx | nasdaq: xrtx), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has received final approval from the tsx venture exchange (the “tsxv”) to list its common shares on the tsxv effective as of the open of market on november 4, 2021 under the share symbol xrtx.
XRTX Ratings Summary
XRTX Quant Ranking